ABSTRACT PulMiCC (Pulmonary Metastasectomy in Colorectal Cancer) is a randomised controlled trial funded by Cancer Research UK. Patients with a history of resected colorectal cancer who are found to have pulmonary metastases are first registered for evaluation and, if subsequently eligible for the trial, they are invited to be randomly allocated to 'active monitoring' or 'active monitoring with pulmonary metastasectomy'. The clinical outcomes are overall survival, relapse-free survival, lung function and patient-reported quality of life.
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From that starting point, the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) trial is best understood as an investigation to discover if active monitoring without pulmonary metastasectomy might result in survival similar to that reported in surgical series when like is compared with like. The evidence available for the effectiveness of metastasectomy is in the form of retrospective case reviews and observational studies. These have been collated in a formally conducted systematic review and a quantitative synthesis of data from 3504 patients in 51 studies. 2 There were no randomised trials. The 5-year survival rates of patients who had pulmonary metastasectomy are of the order of 40%. In only two reports is a denominator provided. These show that metastasectomy was performed in a selected 1e3% of patients with recurrent cancer. Thirty years ago the suggestion was made that this better than expected survival might be an effect of selection rather than surgery. 3 Modelling studies using Thames Cancer Registry data pose the same question. 4 The characteristics of patients in the many retrospective studies have been remarkably consistent since the 1960s: the patients are (in round figures) of average age 60 years, 60% male, 60% have a solitary metastasis, about 60% have low/ normal carcinoma embryonic antigen (CEA) and a median interval of about 36 months has elapsed since the primary resection. In multivariable analyses, the consistent features that favour longer survival are a single metastasis, a long interoperative interval 5 and a low CEA. 6 These three factors are clearly favourable features in terms of the aggressiveness of the cancer: they are prognostic features for all patients with colorectal cancer rather than being predictive of the surgical effectiveness of pulmonary metastasectomy.
However, practice has gone well outside the bounds set in the observational studies. In a recent survey among members of the European Society of Thoracic Surgeons (ESTS), multiple metastases were not a contraindication for 85% of responding surgeons, an interval of less than a year since the primary operation was acceptable for 64% and synchronous metastases for 50%. 7 Whether the reported good survival rates are due to surgery or selection, it cannot be assumed that they will be replicated in a practice which has strayed well outside the criteria employed in the selection of the 3504 patients in the quantitative synthesis. In contrast to the stated practice of the members at large, the ESTS Working Group was unable to offer recommendations for pulmonary metastasectomy on the basis of its findings. 8 The design of PulMiCC is founded upon an uncertainty that must exist in the advice given to many of these patients. Consider two scenarios where advice for or against metastasectomy is reasonably consistent. Patients who have a cluster of the favourable features, such as a single pulmonary metastasis which is evident only after several years and is growing slowly, might be offered metastasectomy as part of widely accepted current practice (although it should be noted that effectiveness of metastasectomy has not been shown and these patients are eligible for randomisation within PulMiCC). In contrast, patients with multiple bilateral metastases, evident within months and growing, are generally advised against metastasectomy. However, between these extremes are patients with a combination of some favourable and some unfavourable features; they are neither an easy 'yes' for metastasectomy nor a confident 'no'. If there is uncertainty, unbiased allocation is as good a basis as any other for making the decision. 9 10 PulMiCC has a two-stage consent process (figure 1) derived from that used in the Mesothelioma and Radical Surgery (MARS) trial where it proved an effective strategy to recruit sufficient patients into a very challenging trial. 11 In the first stage of PulMiCC, any patient with one or more pulmonary nodules which might be from colorectal cancer can be invited to enter the study with no commitment to randomisation. DVDs for medical staff and for patients have been prepared based on evidence-based best practice in presenting uncertainty to patients in a way that is open, even handed and, at the same time, supportive.
12e14 The notion that haste or urgency are helpful should be dispelled. 15 Even if it is not easy to put these matters to patients, for those with demonstrable stage IV colorectal cancer, time measured in days or a couple of weeks is better spent in careful evaluation than hastening towards a thoracotomy.
During this first stage of PulMiCC the operative and pathological details of the primary cancer are reviewed. Where there is a solitary nodule, the possibility of primary lung cancer should be considered by the lung multidisciplinary team. If not already done, PET/CT is arranged. 16 In some cases percutaneous biopsy will be advised. With regard to chemotherapy, we found no evident consensus. Some oncologists give chemotherapy routinely on discovery of recurrence, some believe it has a place in gauging the responsiveness of the disease and some use it as an adjuvant therapy. It can be given during this phase of the study. At the end of this phase there will be some patients for whom there is a decision against surgery and there will be some for whom metastasectomy will be offered on the basis of current practice and beliefs. Between these groups there is a zone of uncertainty.
For patients where there is uncertainty, a randomised allocation will be offered. The randomisation procedure will include minimisation to ensure that the two arms are similar in terms of age, sex, number of metastases, T and N stage of the primary, previous resection of liver metastases and CEA level. 17 18 Patients not allocated to metastasectomy will have 'continued active monitoring'. Radiofrequency ablation or stereotactic radiotherapy are not treatment options within PulMiCC.
The surgical options are left to the local team to decide. The choice between thoracotomy and video-assisted thoracic surgery (VATS) is in large part governed by technical surgical considerations which depend on the size of the metastases and their exact location with respect to the pulmonary vessels. Some contend that the lung should be routinely palpated at thoracotomy to ensure that a complete metastasectomy is performed. 19 This is a reminder that this surgery is not trivial, a notion which has become associated with metastasectomy in a VATS era. Data on symptomatic outcome are lacking and there are very few data on change in pulmonary function associated with metastasectomy. 2 There must be some negative impact attributable to the chest wall incision, interference with the pleura and loss of lung parenchyma. These will be captured, along with patient-reported quality of life outcomes, pulmonary function and survival.
The trial is open for recruitment in an increasing number of UK centres. Full details of PulMiCC can be found on the website (http://www.rbht.nhs.uk/PulMiCC/). 
